Biochemical Alterations of Erythrocytes as an Indicator of Mental Disorders: An Overview

REFERENCES

• Meltzer HL. Is there a specific membrane defect in bipolar disorders? Biol Psychiatry 1991;30:1071–4.
   PubMedGoogle Scholar
• Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994;13:195–207.
   PubMed Web of Science ®Google Scholar
• Horrobin DF. The membrane hypothesis of schizophrenia as a chemical basis for the neurodevelopment concept of schizophrenia. Schizophr Res 1998;30:193–208.
   PubMed Web of Science ®Google Scholar
• Glen AIM, Glen EMT, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fischer N. A red blood cell abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994;12:53–61.
   PubMed Web of Science ®Google Scholar
• Glen AIM, Cooper SJ, Rybakowski J, Vaddadi K, Brayshaw N, Horrobin DF. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids 1996;55:9–15.
   PubMedGoogle Scholar
• Kay SR. Positive and negative syndromes in schizophrenia: assessment and research. New York: Brunner/Mazel, 1991.
   Google Scholar
• Hitzemann RJ, Hirschowitz J, Garver DE. On the physical properties of red cell ghost membranes in the affective disor- ders and psychoses. A fluorescence polarization study. J Affect Disord 1986;10:227–32.
   PubMedGoogle Scholar
• Vilkov GA, Kiroi RI, Stepnina EG, Smirnova OB, Kovalenko VA, Trapezontseva RA. [Lipid peroxidation and microviscosity of erythrocyte membranes in patients with schizophrenia]. Zh Nevropathol Psychiatr im SS Korsakova 1991;91:45–7.
   PubMedGoogle Scholar
• Yao JK, van Kammen DP. Red cell membrane dynam- ics in schizophrenia. I. Membrane fluidity. Schizophr Res 1994;11:209–16.
   PubMedGoogle Scholar
• Ryazantzeva NV, Novitskii VV, Stepovaya EA, Logvinov SV, Miller AA, Luk’yantsev SV. Ultrastructural changes in ery- throcytes in patients with mental disorders. Bull Exp Biol Med 2001;132:1013–6.
   PubMedGoogle Scholar
• Yao JK, van Kammen DP, Welker JA. Red blood cell mem- brane dynamics in schizophrenia. II. Fatty acid composition. Schizoph Res 1994;13:217–26.
   Google Scholar
• Yao JK, van Kammen DP, Gurklis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnor- malities with clinical measures. Schizophr Res 1994;13:227– 32.
   Google Scholar
• Nakashima H, Ueda K, Yasugawa S, Katsugary S, Kimura T, Miykawa T. Erythocyte deformability in schizophrenic pa- tients. Psychiatry Clin Neurosci 1996;50:191–4.
   PubMedGoogle Scholar
• Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first- episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991;48:563–8.
   Google Scholar
• Rybakowski JK, Lehman W. Abnormalities in lithium trans- port across the erythrocyte membrane in depression and schizophrenia. Biol Psychiatry 1991;29:340–6.
   PubMedGoogle Scholar
• Novitskii VV, Ryazantseva NV, Semin IR. Surface architecton- ics of peripheral blood erythrocytes in patients with mental diseases. Bull Exp Biol Med 2000;130:979–82.
   PubMedGoogle Scholar
• Buchonski R, Tabarowski Z, Dabrowski Z. [Changes in ery- throcyte shape in children treated with chlorpromazine]. Folia Med Cracov 1992;33:59–64.
   PubMedGoogle Scholar
• Barshtein G, Ponizovsky AM, Modai I, Ritsner MS, Nechamkin Y, Yedgar S, et al. Aggregability of red blood cells of schizophre- nia patients with negative syndrome is selectively enhanced. Schizophr Bull (in press).
   Google Scholar
• Maes M, Delange J, Ranjan R, Meltzer H, Desnyder R, Cooremans W. Acute phase proteins in schizophrenia, ma- nia and major depression: modulation by psychotropic drugs. Psychiatry Res 1997;66:1–11.
   PubMed Web of Science ®Google Scholar
• Takei M, Yamamoto K, Andou Y, Yamada H. Exercise-induced arterialization of venous blood in some schizophrenics: a fur- ther note on possible microcirculation disturbances. Biol Psy- chiatry 1993;33:139–40.
   PubMedGoogle Scholar
• Sabri O. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. J Nucl Med 1997;38:181–8.
   PubMedGoogle Scholar
• Owega A, Klingelhofer J, Sabri O, Kunert HJ, Albers M, Sass H. Cerebral blood flow velocity in acute schizophrenic pa- tients. A transcranial Doppler ultrasonography study. Stroke 1998;29:1149–54.
   Google Scholar
• Min SK, An SK, Jon DJ, Lee JD. Positive and negative symp- toms and regional cerebral perfusion in antipsychotic naive schizophrenia patients. Psychiatry Res 1999;90:159–68.
   PubMed Web of Science ®Google Scholar
• Erkwoh R, Sabri O, Willmes K, Steinmeyer EM, Bull U, Sars H. Active and remitted schizophrenia: psychopatholog- ical and regional blood flow findings. Psychiatry Res 1999;90:17–30.
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001;15:287–310.
   PubMed Web of Science ®Google Scholar
• Ramchand CN, Davies JI, Tresman RL, Griffiths ICD, Peet M. Reduced susceptibility to oxidative damage of erythro- cyte membranes from medicated schizophrenic patients. Prostaglandins Leukot Essent Fatty Acids 1996;55:27–31.
   PubMedGoogle Scholar
• Mahadik SP, Mukherjee S, Correnti EE, Scheffer R, Mahadik J. Elevated plasma lipid peroxides at the onset of non-affective psychosis. Biol Psychiatry 1998;43:674–9.
   PubMed Web of Science ®Google Scholar
• Herken H, Uz E, Sogut S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001;6:66–73.
   PubMed Web of Science ®Google Scholar
• Altuntas I, Aksoy H, Coskun I, Caykoylu A, Akcay F. Erythro- cyte superoxide dismutase and glutathione peroxidase activi- ties, and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med 2000;38:1277–81.
   PubMed Web of Science ®Google Scholar
• Kut’ko II, Frolov VM, Pustovoi IuG, Rachkauskas GS, Pavlenko VV. [Antioxidants in the treatment of schizophrenia (the correction of lipid peroxidation processes)]. Zh Nevropatol Psikhiatr ImSS Korsakova 1996;96:32–4.
   PubMedGoogle Scholar
• Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal sub- jects. Psychiatry Res 1996;63:133–42.
   PubMed Web of Science ®Google Scholar
• Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 2003;53:56–64.
   PubMed Web of Science ®Google Scholar
• Khan NS, Das I. Oxidative stress and superoxide dismutase activity in schizophrenia. Biochem Soc Trans 1997;25:418S.
   Google Scholar
• Golse B, Debray Q, Puget K, Michelson AM. Dosages ery- throcytaires de la superoxyde dismutase 1 et de la glutathion peroxydase dans les schizophrenies de l’adulte. Nouv Pr Med 1978;7:2070–1.
   PubMedGoogle Scholar
• Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. Activ- ities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 1986;32:805–7.
   PubMed Web of Science ®Google Scholar
• Reddy R, Sahebarao MP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenia pa- tients. Biol Psychiatry 1991;30:409–12.H. Sinet PM, Debray Q, Carmagnol F, Pelicier Y, Nicole A, Jerome Normal erythrocyte SOD values in two human diseases: schizophrenia and cystic fibrosis. In: Cohen G, Greenwald RA, eds. Oxy radicals and their scavenger systems: Vol. 2. Cellular and medical aspects. New York: Elsevier Scientific, 1983:302– 4.
   Google Scholar
• Yao JK, Reddy R, van Kammen DP, Kelley ME. Superoxide dismutase and negative symptoms in schizophrenia. Biol Psy- chiatry 1998; 43:123S–4S.
   Google Scholar
• Vaiva G, Thomas P, Leroux JM, Cottencin O, Dutoit D, Erb F, et al. [Erythrocyte superoxide dismutase (eSOD) determi- nation in positive moments of psychosis]. Therapie 1994; 49:343–8.Mukerjee S, Mahadik SP, Schefferm R, Correnti EE, Kelkar Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996;19:19–26.
   Google Scholar
• Yao JK, Reddy R, McElhinny LG, van Kammen DP. Effect of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998;32:385–91.
   PubMed Web of Science ®Google Scholar
• Yamada I, Kanba S, Anamizu S, Onishi K, Ashikari I, Yagi G, et al. Low superoxide dismutase actvity in schizophrenic patients with tardive dyskinesia. Psychol Med 1997;27:1223–5.
   PubMedGoogle Scholar
• Yao JK. Red blood cell and platelet fatty acid metabolism in schizophrenia. In: Peet M, Glen I, Horrobin DF, eds. Phos- pholipid spectrum disorder in psychiatry. Carnforth, England: Marius, 1999:57–71.
   Google Scholar
• Mahadik SP, Sitasawad S, Mulchandani M. Membrane perox- idation and the neuropathology of schizophrenia. In: Peet M, Glen I, Horrobin DF, eds. Phospholipid spectrum disorder in psychiatry. Carnforth, England: Marius, 1999:99–112.
   Google Scholar
• Cho HW, Meltzer HK. Mg++-dependent adenosine triphos- phatase activity in erythrocyte ghosts of schizophrenia pa- tients. Biol Psychiatry 1974;9:109–16.
   PubMedGoogle Scholar
• Hokin-Neaverson M, Jefferson JW. Erythrocyte sodium pump activity in bipolar affective disorder and other psychiatric dis- orders. Neuropsychobiology 1989;22:1–7.
   PubMedGoogle Scholar
• Hokin-Neaverson M, Jefferson JW. Deficient erythrocyte Na- K activity in different affective states in bipolar affective disorder and normalization by lithium therapy. Neuropsy- chobiology 1989;22:18–25.
   PubMedGoogle Scholar
• Rybakowski J, Lehmann W. Decreased activity of erythrocyte membrane ATPases in depression and schizophrenia. Neu- ropsychobiology 1994;30:11–4.
   Google Scholar
• Morere DA, Alarcon RD, Monti DA, Walter-Ryan WG, Bancroft AJ, Smythies JR. Medication effects on one-carbon metabolism in schizophrenia, mania and major depression. J Clin Psy- chopharmacol 1986;6:155–61.
   Google Scholar
• Smythies JR, Alarcon DR, Morere D, Monti JA, Steele A, Tolbert LC, et al. Abnormalities of one-carbon metabolism in psychiatric disorders: study of kinetics and lipid composition of erythrocyte membranes. Biol Psychiatry 1986;21:1391–8.
   PubMedGoogle Scholar
• Gomes-Trolin C, Yassin M, Gottfries CG, Regland B, Grenfeldt B, Hallman B. Erythrocyte and brain methionin adenosyl- transferase activities in patients with schizophrenia. J Neural Transm 1998;105:1293–305.
   PubMedGoogle Scholar
• Zilberman-Kaufman M, Agam G, Moscowits L, Livne AA, Belmaker RH. Raised monophosphatase activity in schizophrenic patients. Clin Chim Acta 1992;209:89–93.
   PubMedGoogle Scholar
• Moscovich DG, Belmaker RH, Agam G, Livne AA. Inositol-1- phosphatase in red blood cells of manic-depressive patients before and during treatment with lithium. Biol Psychiatry 1990;27:552–5.
   PubMed Web of Science ®Google Scholar
• Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O. Erythrocyte ketonereductase activity, to- tal plasma haloperidol and acute psychoses. Encephale 1996;21:417–24.
   Google Scholar
• Someya T, Shibasaki M, Kato T, Noguchi T, Ishida N, Takahashi S. Haloperidol reductase activity in red blood cells from oriental patients on haloperidol. Progr Neuropsychophar- macol Biol Psychiatry 1991;15:275–8.
   PubMedGoogle Scholar
• Aymard N, Viala A, Stein I, Caroli F. Pharmacoclinical corre- lations in schizophrenic patients treated with haloperidol de- canoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. Progr Neuropsychopharmacol Biol Psychi- atry 1995;19:1119–35.
   PubMedGoogle Scholar
• Minetti G, Low PS. Erythrocyte signal transduction pathways and their possible functions. Curr Opn Hematol 1997;4:116– 21.
   Google Scholar
• Tang LC. Identification and characterization of human ery- throcyte muscarinic receptors. Gen Pharmacol 1986;17:281–5.
   PubMedGoogle Scholar
• Tang LC. Human erythrocyte as a model for investigat- ing muscarinic agonists and antagonists. Gen Pharmacol 1991;22:485–90.
   PubMedGoogle Scholar
• Bering B, Muller WE. Specific 3H-QNB binding to human ery- throcyte membranes associated with muscarinic cholinergic receptors. J Neural Transm 1987;68:97–111.
   PubMedGoogle Scholar
• Huestis WH, McConnel HM. A functional acetylcholine recep- tor in the human erythrocyte. Biochem Biophys Res Comm 1974;57:728–32.
   Google Scholar
• Tang LC, Schoomaker E, Wiesmann WP. Cholinergic agonists stimulate calcium uptake and cGMP formation in human ery- throcytes. Biochem Biophys Acta 1984;772:235–8.
   PubMedGoogle Scholar
• Tandon R, Greden JF. Cholinergic hyperactivity and neg- ative schizophrenia symptoms: a model of cholinergic- dopaminergic interactions in schizophrenia. Arch Gen Psychi- atry 1989;46:745–53.
   PubMed Web of Science ®Google Scholar
• Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson JA. Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symp- toms. Schizophr Res 1991;4:23–30.
   Google Scholar
• Carlson SE, Carver JD, House SC. High fat diets varying ratios of polyunsaturated to saturated fatty acids and linoleic acid: a comparison of rat neural and red cell phospholipids. J Nutr 1986;116:718–25.
   PubMed Web of Science ®Google Scholar
• Bourre JM, Bonneil M, Chaudiere J, Clement M, Dumont O, Durand G. Structural and functional importance of dietary polyunsaturated fatty acids in the nervous system. Adv Exp Med Biol 1992;318:211–29.
   PubMedGoogle Scholar
• Babin F, Sarda P, Limasset B, Decomps B, Rieu D, Mendy F. Nervonic acid in red blood cell sphingomyelin in premature infants: an index of myelin maturation? Lipids 1993;28:627– 30.
   Google Scholar
• Connor WE, Lin DS, Neuringer M. Is the docohexaenoc acid (DHA 22:6, ω-3) content of erythrocytes a marker for the DHA content of brain phospholipids? FASEB J 1993; 7:152.
   Google Scholar
• Makrides M, Neumann MA, Byard RW, Simmer K, Gibson RA. Fatty acid composition of brain, retina and erythro- cytes in breast and formula-fed infants. Am J Clin Nutrition 1994;60:189–94.
   PubMed Web of Science ®Google Scholar
• Stevens JD. The distribution of phospholipid fractions in red cell membranes of schizophrenics. Schizophr Bull 1972;6:60–1.
   Google Scholar
• Sengupta N, Datta SC, Sengupta D. Platelet and erythrocyte membrane lipid and phospholipid patterns in different types of mental patients. Biochem Med 1981;25:267–75.
   PubMedGoogle Scholar
• Lautin A, Cordasco DM, Segarnik D, Wood L, Mason FM, Wolkin A, et al. Red cell phospholipids in schizophrenia. Life Sci 1982;31:3051–6.
   PubMedGoogle Scholar
• Hitzemann R, Garver D. Membrane abnormalities in schizophrenia patients. Psychopharm Bull 1982;18:190–2.
   PubMedGoogle Scholar
• Hitzemann R, Mark C, Hirschowitz J, Garver D. Characteris- tics of phospholipid methylation in human erythrocyte ghosts: relationship(s) to the psychosis and affective disorders. Biol Psychiatry 1985;20:397–407.
   PubMedGoogle Scholar
• Keshavan MS, Mallinger AG, Pettegrew JW, Dippold C. Ery- throcyte membrane phospholipids in psychotic patients. Psy- chiatr Res 1994;49:89–95.
   Google Scholar
• Ponizovsky AM, Modai I, Nechamkin Y, Barshtein G, Ritsner MS, Yedgar S, et al. Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology. Schizophr Res 2001;52:121–6.
   PubMed Web of Science ®Google Scholar
• Hitzemann R, Hirschowitz J, Garver D. Membrane abnormal- ities in the psychoses and affective disorders. J Psychiatry Res 1984;8:319–26.
   Google Scholar
• Tolbert LC, Monti JA, O’Shields H, Walter-Ryan W, Meadows D, Smythies JR. Defects in transmethylation and membrane lipids in schizophrenia. Psychopharm Bull 1993;29:594–9.
   Google Scholar
• Mahadik SP, Mukherjee S, Correnti EE, Kelkar HS, Wakade CG, Costa LM, et al. Plasma membrane cholesterol and phospholipid distribution of skin fibroblasts from drug naive patients at the onset of psychosis. Schizophr Res 1994;13:239– 47.
   Google Scholar
• Yao JK, Leonard S, Reddy RD. Membrane phospholipid ab- normalities in postmortem brains from schizophrenic patients. Schizophr Res 2000;42:7–17.
   PubMed Web of Science ®Google Scholar
• Ryazantseva NV, Novitskii VV, Kublinskaya MM. Changes in the lipid phase of erythrocyte membranes in patients with paranoid schizophrenia. Bull Exp Biol Med 2002;133:84–6.
   PubMedGoogle Scholar
• Hasselhorst U, Schenk H, Beyer I, Uebelhack R, Franke E, Kielstein V. Abnormality of gangliosides in erythrocyte membranes of schizophrenic patients. Clin Physiol Biochem 1988;6:281–4.
   PubMedGoogle Scholar
• Liu Y, Wada R, Kawai H, Sango K, Deng C, Tai T, et al. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J Clin Invest 1999;103:497–505.
   PubMed Web of Science ®Google Scholar
• Obi FO, Nwanze EAC. Fatty acid profiles in mental disease. Part 1. Linolenate variations in schizophrenia. J Neurol Sci 1979;43:447–54.
   PubMedGoogle Scholar
• Vaddadi KS, Gilleard CJ, Mindham RHS, Butler R. A con- trolled trial of prostaglandin E1 precursors in chronic neu- roleptic resistant schizophrenic patients. Psychopharmacol- ogy (Berl) 1986;88:362–7.
   PubMed Web of Science ®Google Scholar
• Vaddadi KS, Gileard CJ, Soosai E, Polonowita AK, Gibson RA, Burrow G. Schizophrenia, tardive dyskenesia and essential fatty acids. Schizophr Res 1996;20:286–94.
   Google Scholar
• Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: de- creased ω3-fractions in cholesterol esters and increased C20: 4ω6/C20:5ω3 ratio in cholesterol esters and phospholipids. J Affect Disord 1996;38:35–46.
   PubMed Web of Science ®Google Scholar
• Peet M, Laugharne JDE, Horrobin DF, Reynolds GP. Arachi- donic acid: a common link in the biology of schizophrenia? Arch Gen Psychiatry 1994;51:665–6.
   PubMed Web of Science ®Google Scholar
• Peet M, Laugharne J, Rangarajan N, Horrobin DF, Reynolds GP. Depleted red cell membrane essential fatty acids in drug treated schizophrenia patients. J Psychiatr Res 1995;29:227– 32.
   Google Scholar
• Peet M, Laugharne JDE, Mellor J, Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 1996:55:71–5.
   PubMedGoogle Scholar
• Peet M, Edwards RW. Lipids, depression and physical diseases. Curr Opin Psychiatry 1997;10:477–80.
   Web of Science ®Google Scholar
• Peet M, Murphy B, Shay B, Horrobin DF. Depletion of omega-3 fatty acids in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315–9.
   PubMed Web of Science ®Google Scholar
• Laugharne JDE, Mellor JE, Peet M. Fatty acids and schizophrenia. Lipids 1996;31(suppl): S163–5.
   Google Scholar
• Doris AB, Wahle K, MacDonald A, Morris S, Coffey I, Muir W. Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia. Schizophr Res 1998;31:185–96.
   PubMedGoogle Scholar
• Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte mem- branes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 2001;49:510–22.
   PubMed Web of Science ®Google Scholar
• Evans DR, Mahadik SP, Akin J, Evans W, Jain D. Cell mem- brane essential fatty acid status in drug-naive first-episode psychotic patients and its relation to outcome. Schizophr Res 2001;49:83.
   Google Scholar
• Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002;58:1–10.
   PubMed Web of Science ®Google Scholar
• Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000;47:8–21.
   PubMed Web of Science ®Google Scholar
• Walker NS, Fox HC, Whalley LJ. Lipids and schizophrenia. Br J Psychiatry 1999;174:101–4.
   PubMedGoogle Scholar
• Yao JK, Reddy RD. Fatty acid and psychiatric disorders. In: Chow CK, ed. Fatty acids in foods and their health implica- tions. 2nd ed. Mariel Dekker: New York, 2000:995–1012.
   Google Scholar
• Horrobin DF, Glen AIM, Cantrill RC. Clozapine: elevation of membrane unsaturated lipid levels as a new mechanism of action. Schizophr Res 1997;24:214–9.
   Google Scholar
• Horrobin DF. The phospholipid concept of psychiatric disor- ders and its relationship to the neurodevelopment concept of schizophrenia. In: Peet M, Glen I, Horrobin DF, eds. Phos- pholipid spectrum disorder in psychiatry. Carnforth, England: Marius, 1999:3–22.
   Google Scholar
• Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 1989;27:313– 23.
   Google Scholar
• Fischer S, Werner K, Kub HJ. Schizophrenic patients treated with high dose phenothiazine or thioxanthene become defi- cient in polyunsaturated acids in their thrombocytes. Biochem Pharmacol 1992;44:317–23.
   PubMedGoogle Scholar
• Mahadik SP, Shenkardar NS, Scheffer R, Mukherjee S, Correnti EE. Utilization of precursor fatty acids in culture by skin fibroblasts from schizophrenic patients and normal con- trols. Prostaglandins Leukot Essent Fatty Acids 1996;55:65– 70.
   Google Scholar
• Ramchand CN, Das I, Ramchand R, Lee KH, Peet M. Biochem- ical alterations associated with membrane abnormalities in schizophrenia: a study using fibroblasts from schizophrenics. Schizophr Res 1997;24:66–7.
   Google Scholar
• Horrobin DF, Manku MS, Morsefisher N, Vaddadi KS, Kourtney P, Glen AIM, et al. Essential fatty acids in plasma phospholipids in schizophrenia. Biol Psychiatry 1989;25:562– 8.
   Google Scholar
• Kaiya H, Horrobin DF, Manku MS, Morse-Fisher N. Essen- tial and other fatty acids in plasma from schizophrenics and normal individuals from Japan. Biol Psychiatry 1991;30:357–62.
   PubMedGoogle Scholar
• Bates C, Horrobin DF, Ellis K. Fatty acids in plasma phos- pholipids and cholesterol esters from identical twins concor- dant and disconcordant for schizophrenia. Schizophr Res 1991; 6:1–7.
   PubMedGoogle Scholar
• Horrobin DF, Manku MS, Hillman H, Iain A, Glen AIM. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 1991;25:562–8.
   Google Scholar
• 76606401003554000Reddy R, Yao JK. Membrane-protective strategies in schizophrenia. In: Peet M, Glen I, Horrobin DF, eds. Phos- pholipid spectrum disorder in psychiatry. Carnforth, England: Marius, 1999:75–88.
   Google Scholar
• Rybakowski J, Wieterle R. Niacin test in schizophrenia and affective illness. Biol Psychiatry 1991;29:834–6.
   PubMed Web of Science ®Google Scholar
• Ward PE, Sutherland J, Glen EM, Glen AJ. Niacin skin flush in schizophrenia: a preliminary report. Schizophr Res 1998;29:269–74.
   PubMedGoogle Scholar
• Easton T, Hirsch SR, Das J, Kidane L, Richardson AJ, Puri BK. The relationship of the area under niacin flush dose-response curve and schizophrenia status. Schizophr Res 2000;41:244–8.
   Google Scholar
• Horrobin DF, Glen AIM, Glen EMT, Skinner F. Red cell mem- brane fatty acids in schizophrenic patient with mainly positive or mainly negative symptoms. Schizophr Res 1993;9:221–6.
   Google Scholar
• Gattaz WF, Hubner CK, Nevalainen TJ, Thuren T, Kinnunen PKJ. Increased serum phospholipase activity in schizophrenia: a replication study. Biol Psychiatry 1990;28:495–501.
   PubMed Web of Science ®Google Scholar
• Gattaz WF, Steudle A, Maras A. Increased phospholipase A2 activity in schizophrenia. Schizophr Res 1995;16:1–6.
   PubMed Web of Science ®Google Scholar
• Gattaz WF, Brunner J. Phospholipase A2 and the hypofrontal- ity hypothesis of schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996;55:109–13.
   PubMedGoogle Scholar
• Ross BM. Brain and blood phospholipases in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1997;57:212–4.
   Google Scholar
• Ross B, Hudson C, Ehrlich J, Warsh JJ, Kisch SJ. Increased phospholipid breakdown in schizophrenia. Arch Gen Psychia- try 1997;54:487–94.
   PubMed Web of Science ®Google Scholar
• Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, et al. Elevated PLA2 activity in schizophrenia and other psychiatric patients. Biol Psychiatry 1993;34:641–9.
   PubMed Web of Science ®Google Scholar
• Albers M, Meurer H, Marki F, Klotz J. Phospholipase A2 activ- ity in serum of neuroleptic-na¨ıve psychiatric inpatients. Phar- macopsychiatry 1993;26:94–8.
   PubMedGoogle Scholar
• Ross BM, Moszynski A, Warsh JJ, Kish SJ. Differential alter- ations of phospholipase A2 activities in the brain of patients with schizophrenia. Brain Res 1999;821:407–13.
   PubMed Web of Science ®Google Scholar
• Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen PKJ. Increased plasma phospholipase A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry 1987;22:421–6.
   PubMed Web of Science ®Google Scholar
• Michalak J, Kadziolka A, Pruszkowska R, Ledwoziw A, Madejczik A. Compensatory mechanisms in erythrocyte lipid in patients with atherosclerosis. Lipids 1988;23:476–80.
   PubMedGoogle Scholar
• Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Morrison-Stewart S, et al. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spec- troscopy study. Schizophr Res 1994;13:209–15.
   PubMed Web of Science ®Google Scholar
• Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Malla A, et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phos- phorus magnetic resonance spectroscopy. Arch Gen Psychiatry 1995;52:399–406.
   PubMed Web of Science ®Google Scholar
• Viktorov AV, Barsukov LI, Muzya GI, Bergelson LD. [Influ- ence of lipid peroxidation and lysolecithin on transbilayer phospholipid migration]. Doklady Akad Nauk SSSR 1979;245:1243–6.
   Google Scholar
• Lundbaek J, Andersen O. Lysophospholipids modulate chan- nel function by altering the mechanical properties of lipid bi- layers. J Gen Physiol 1994;104:545–73.
   Google Scholar
• Hudson CJ, Lin A, Horrobin DF. Phospholipases: in search for a genetic basis of schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996;55:115–8.
   PubMedGoogle Scholar
• Hudson CJ, Kennedy JL, Gotowiec A. Genetic variants near cytosolic phospholipase A2 associated with schizophrenia. Schizophr Res 1996;21:111–6.
   PubMedGoogle Scholar
• Price SA, Fox H, St Clair D, Show DJ. Lack of association be- tween schizophrenia and polymorphism close to the cytosolic phospholipase A2 gene. Psychiatr Genet 1997;7:111–4.
   PubMedGoogle Scholar
• Peet M, Ramchand CN, Lee KH, Telang SD, Vankar GK, Shah S, et al. Association of the Ban I dimorphic site at the human phospholipase A2 gene with schizophrenia. Psychiatr Genet 1998;3:1–2.
   Google Scholar
• Ramchand CN, Wei J, Lee KH, Peet M. Phospholipase A2 gene polymorphism and associated biochemical alterations in schizophrenia. In: Peet M, Glen I, Horrobin DF, eds. Phos- pholipid spectrum disorder in psychiatry. Carnforth, England: Marius, 1999:31–8.
   Google Scholar
• Azorin JM, Bovier P, Chiaroni P, Dufour H, Gaillard GM, Jeanningros J, et al. Advanced 7 years study of erythrocyte membrane transport of monoamine precursors in 395 pa- tients (335 depressed, 60 schizophrenic patients). Encephale 1994:20:111–9.
   PubMedGoogle Scholar
• Serres F, Dassa D, Azorin M, Jeanningros R. Decrease in red blood cell L-tryptophan uptake in schizophrenic patients: pos- sible link with loss of impulse control. Progr Neuropsychophar- macol Biol Psychiatry 1995;19:903–13.
   PubMedGoogle Scholar
• Naylor GI, Dick DAT, Dick EG, LePoidevin D, White SF. Ery- throcyte membrane cation carrier in depressive illness. Psy- chol Med 1973;3:502–8.
   Google Scholar
• Hesketh JE, Glen AIM, Reading HW. Membrane ATPase ac- tivities in depressive illness. J Neurochem 1977;28:1401–2.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Taylor MA, Abrams R. Depression, ETC and ery- throcyte adenosine triphosphatase activity. Biol Psychiatry 1977;12:75–81.
   PubMedGoogle Scholar
• Rybakowski J, Potok E, Strzyzewski W. Erythrocyte mem- brane adenosine triphosphatase activities in patients with en- dogeneous depression and healthy subjects. Eur J Clin Invest 1981;11:51–64.
   Google Scholar
• Looney SW, el-Mallakh RS. Meta-analysis of erythrocyte Na-K ATPase activity in bipolar illness. Depress Anx 1997;5:53–65.
   Google Scholar
• Meltzer HK, Kassir S. Abnormal calmoduline activated ATPase in manic-depressive subjects. J Psychiatr Res 1983;17:29–35.
   Google Scholar
• Meltzer HK, Kassir S, Goodnick PJ, Fieve RR, Chrisomalis L, Feliciano M, et al. Calmodulin-activated calcium ATPase in bipolar illness. Neuropsychology 1988;20:169–73.
   Google Scholar
• Kassir S, Meltzer HK. Abnormal sensitivity of erythrocyte membrane Na/K ATPase of bipolar subjects to inhibition by calmodulin and calcium. Biol Psychiatry 1991;30:631–4.
   PubMedGoogle Scholar
• Karege F, Bovier P, Gaillard JM, Tissot R. The decrease of ery- throcyte catechol-O-methyltransferase activity in depressed patients and its diagnostic significance. Acta Psychiatr Scand 1987;76:303–8.
   PubMed Web of Science ®Google Scholar
• Moises HW, Bering B, Muller WE. Personality factors predisposing to depression correlate significantly with M1-muscarinic and beta-adrenergic receptor densities on blood cells. Arch Psychiatry Neurol Sci 1988;237:209–17.
   PubMedGoogle Scholar
• Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachi- donic acid to eicosapentaenoic acid ratio in blood corre- lates positively with clinical symptoms of depression. Lipids 1996;31(suppl): S157–61.
   Google Scholar
• Seko C, Ninno N, Nakamuro K. Relationship between fatty acid composition in blood and depressive symptoms in the el- derly. Jpn J Hyg 1997;52:330–5.
   Google Scholar
• Edwards RW, Peet M, Shay J, Horrobin D. Omega-3 polyun- saturated fatty acid levels in the diet and red blood cell mem- branes of depressed patients. J Affect Disord 1998;48:149–55.
   PubMed Web of Science ®Google Scholar
• Edwards RW, Peet M. Essential fatty acids in relation to de- pression. In: Peet M, Glen I, Horrobin DF, eds. Phospholipid spectrum disorder in psychiatry. Cornforth, England: Marius, 1999:211–24.
   Google Scholar
• Horrobin DF, Bennet CN. Depression and bipolar disorder: re- lationships to impaired fatty acid phospholipid metabolism and to diabetes, cardiovascular disease, immunological ab- normalities, cancer, ageing and osteoporosis. Prostaglandins Leukot Essent Fatty Acids 1999;60:217–34.
   PubMed Web of Science ®Google Scholar
• Corrigan FM, Mowat B, Skinner ER, Van Rhijn AG, Cousland G. High density lipoprotein fatty acids in dementia. Prostaglandins Leukot Essent Fatty Acids 1998;58:125–7.
   PubMedGoogle Scholar
• Horrobin DF, Glen AIM, Hudson CJ. Possible relevance of phospholipid abnormalities and genetic interactions in psy- chiatric disorders: the relationship between dyslexia and schizophrenia. Med Hypotheses 1995;6:605–13.
   Google Scholar
• Carney MWP, Chang TKN, Laundy M, Bottiglieri T, Chanarin I, Reynolds EH. Red cell folate concentrations in psychiatric patients. J Affect Disord 1990;19:207–13.
   PubMed Web of Science ®Google Scholar
• Godfrey PSA, Toone BK, Carney MWP, Flynn TG, Bottiglieri T, Laundy M. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392–4.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Meltzer HL. Increased content of minor ankyrin in erythrocyte membranes of bipolar subjects. Psychiatr Res 1989;27:267–75.
   PubMedGoogle Scholar
• Zhang Y, Placidi GF, Meltzer HL. An abnormal membrane pro- tein in bipolar subjects is independent of treatment modality. Clin Pharmacol Ther 1990;47:136.
   Google Scholar
• Goekop JG, Hoeksema T, Van Kempen JM, Van der Velde EA, Spies F. Osmotic behavior of erythrocytes from patients with a major affective disorder. J Affect Disord 1990;19:139–47.
   PubMedGoogle Scholar
• Arndt S, Alliger RJ, Andreasen NC. The distinction of posi- tive and negative symptoms. The failure of a two-dimensional model. Br J Psychiatry 1991;158:317–22.
   Google Scholar
• Peralta V, Cuesta MJ. Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psy- chiatry Res 1994;53:31–40.
   Google Scholar
• Peralta V, de Leon J, Cuesta MJ. Are there more than two syn- dromes in schizophrenia? A critique of the positive-negative dichotomy. Br J Psychiatry 1992;161:335–43.
   PubMed Web of Science ®Google Scholar
• Xiao YF, Gomez AM, Morgan JP, Lederern WJ, Leaf A. Sup- pression of voltage-gated L-type Ca2+ currents by polyunsat- urated fatty acids in adult and neonatal rat ventricular my- ocytes. Proc Natl Acad Sci USA 1997;94:4182–7.
   PubMed Web of Science ®Google Scholar
• Hannun YA. The sphingomyelin cycle and the second messen- ger function of ceramide. J Biol Chem 1994;269:3125–8.
   PubMed Web of Science ®Google Scholar
• Sawai H, Hannun YA. Ceramide and sphingomyelinases in the regulation of stress responses. Chem Phys Lipids 1999;102:141–7.
   PubMedGoogle Scholar
• Waddington JL. Schizophrenia, developmental neuroscience and pathobiology. Lancet 1993;341:531–6.
   PubMed Web of Science ®Google Scholar
• Weinberger DR. Schizophrenia: from neuropathology to neu- rodevelopment. Lancet 1995;346:552–7.
   PubMed Web of Science ®Google Scholar
• Bergelson LD. Dynamic lipid heterogeneity and receptor events. Molec Membrane Biol 1995;12:125–9.
   PubMed Web of Science ®Google Scholar
• Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapen- taenoic acid in the treatment of schizophrenia. Schizophr Res 2001;49:243–51.
   PubMed Web of Science ®Google Scholar
• Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913–9.
   PubMed Web of Science ®Google Scholar
• Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Arch Gen Psychiatry 1998;55:188–9.
   PubMed Web of Science ®Google Scholar
• Puri BK, Richardson AJ, Horrobin DF, Eaton T, Saeed N, Oatridge A, et al. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisa- tion of blood fatty acids, reduced neuronal membrane phospho- lipid turnover and structural brain changes. Int J Clin Pract 2000;54:57–63.
   PubMed Web of Science ®Google Scholar
• Stoll AL, Locke CA, Marangell LB, Severus WE. Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins Leukot Essent Fatty Acids 1999;60:329–37.
   PubMed Web of Science ®Google Scholar
• Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407–12.
   PubMed Web of Science ®Google Scholar
• Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psy- chotherapeutic agent for a pregnant schizophrenic patient. Eur Neuropsychopharmacol 2001;11:295–9.
   PubMed Web of Science ®Google Scholar
• Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Ran- domized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psy- chiatry 2002;159:1596–8.
   PubMed Web of Science ®Google Scholar
• Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipo- lar depressive disorder. Am J Psychiatry 2002;159:477–9.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003;160:167–9.
   PubMed Web of Science ®Google Scholar
• Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the out- come of schizophrenia. Schizophr Res 2003;62:195–204.
   PubMed Web of Science ®Google Scholar
• Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicos- apentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001;158:2071–4.
   PubMed Web of Science ®Google Scholar